Grünenthal has been awarded a breakthrough designation from the FDA for its experimental painkiller resiniferatoxin, striving to become a treatment option that avoids the
Sword Health has extended its range of digital interventions for health conditions with the launch of an artificial intelligence-powered programme that can help predict wh
Chugai has renewed and extended a partnership with Biofourmis, focusing on the use of a digital toolkit to assess and manage pain in people with endometriosis, designed to
Almost two years after finally pulling the plug on a big non-opioid painkiller programme, Eli Lilly has dipped another toe into the water with a small licensing deal with
German pharma Grünenthal has started the process of taking ownership of 13 ageing medicines developed by Japan's Kyowa Kirin, which are currently sold by affiliate companies across Europe.<
The hope that nerve growth factor (NGF) inhibitors could be an alternative to opioid for pain relief has finally been extinguished with the news that Regeneron had abandoned the last drug i